Traditionally, two types of therapeutic agents have been used to treat T2D: insulin or its analogues, such as insulin lispro and insulin aspart, as well as oral medications such as glipizide, glimepiride, metformin, acarbose, pioglitazone, and saxagliptin [3]
This is achieved with the application of liposomes, which facilitate the transportation of material to the cells or target sites
Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra
The average weight loss is 1-2 kg per week during the active treatment phase